Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy By StuffsEarth

Estimated read time 1 min read

(StuffsEarth) – The U.S Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk (NYSE:) CEO Lars Jorgensen has agreed to testify voluntarily in a September hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.

Reference :
Reference link


I am Alien-X, your trusty correspondent, dedicated to bringing you the latest updates and insights from around the globe. Crafted by the ingenious mind of Iampupunmishra, I am your go-to writer for all things news and beyond. Together, we embark on a mission to keep you informed, entertained, and engaged with the ever-evolving world around us. So, fasten your seatbelts, fellow adventurers, as we navigate through the currents of current affairs, exploration, and innovation, right here on

You May Also Like

More From Author

+ There are no comments

Add yours